Late-onset hypogonadism among old and middle-aged males with prediabetes in Polish population

References

• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37:S81–90
   PubMed Web of Science ®Google Scholar
• Rydén L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2014;27:133–73
   Google Scholar
• Cho NH, Whiting D, Guariguata L. IDF diabetes atlas. 6th ed. Brussels, Belgium: International Diabetes Federation; 2013
   Google Scholar
• Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004;89:5462–8
   PubMed Web of Science ®Google Scholar
• Corona G, Mannucci E, Petrone L, et al. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res 2006;18:190–7
   PubMed Web of Science ®Google Scholar
• Kapoor D, Aldred H, Clark S, et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911–7
   PubMed Web of Science ®Google Scholar
• Grossmann M, Thomas MC, Panagiotopoulos S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008;93:1834−40
   PubMedGoogle Scholar
• Stellato RK, Feldman HA, Hamdy O, et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care 2000;23:490–4
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036–41
   PubMed Web of Science ®Google Scholar
• Beatrice AM, Dutta D, Kumar M, et al. Testosterone levels and type 2 diabetes in men: current knowledge and clinical implications. 1. Diabetes Metab Syndr Obes 2014;7:481–6
   PubMedGoogle Scholar
• Mazur A, Westerman R, Werdecker A, Mueller U. Testosterone and type 2 diabetes in men. Aging Male 2014;1:18–22
   Google Scholar
• Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002;87:589−98
   PubMedGoogle Scholar
• Lunenfeld B, Mskhalaya G, Kalinchenko S, Tischova T. Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men – a suggested update. Aging Male 2013;4:143–50
   Web of Science ®Google Scholar
• Corona G, Rastrelli G, Balercia G, et al. Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. Sex Med 2012;9:1669–80
   PubMed Web of Science ®Google Scholar
• Ho CH, Yu HJ, Wang CY, et al. Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome. PLoS One 2013;8:e74173. doi:10.1371/journal.pone.0074173
   PubMed Web of Science ®Google Scholar
• Rabijewski M, Papierska L, Piątkiewicz P. The prevalence of prediabetes in population of Polish men with late-onset hypogonadism. Aging Male 2014;17:141–146
   PubMed Web of Science ®Google Scholar
• Athyros GV, Ganotakis ES, Mikhailidis DO. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 2005;21:1157–64
   PubMed Web of Science ®Google Scholar
• Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319–26
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72
   PubMed Web of Science ®Google Scholar
• Saukkonen T, Cederberg H, Jokelainen J, et al. Limited overlap between intermediate hyperglycemia as defined by A1C. 5.7–6.4%, impaired fasting glucose, and impaired glucose tolerance. Diabetes Care 2011;34:2314–16
   PubMed Web of Science ®Google Scholar
• Kim ML, Rolland O, Cepeda JK, et al. Diabetes mellitus in older men. Aging Male 2006;9:139–47
   PubMed Web of Science ®Google Scholar
• Atlantis E, Lange K, Martin S, et al. Testosterone and modifiable risk factors associated with diabetes in men. Maturitas 2011;68:279–85
   PubMedGoogle Scholar
• Rabijewski M, Papierska L, Kozakowski J, Zgliczyński W. The high prevalence of testosterone deficiency in population of Polish men over 65 years with erectile dysfunctions. Aging Male 2012;15:258–62
   PubMed Web of Science ®Google Scholar
• Rabijewski M, Papierska L, Zgliczyński W, Piątkiewicz P. The Incidence of hypogonadotropic hypogonadism in type 2 diabetic men in Polish population. Biomed Res Int 2013;2013:767496. doi:10.1155/2013/767496
   PubMedGoogle Scholar
• Colangelo LA, Ouyang P, Liu K, et al. Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: Multi-Ethnic Study of Atherosclerosis. Diabetes Care 2009;32:1049–51
   PubMed Web of Science ®Google Scholar
• Salving E, Finley M, Zhang L, et al. Androgens and diabetes in men. Results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007;30:234–8
   PubMedGoogle Scholar
• Pitteloud N, Dwyer AA, DeCruz S, et al. The relative role of gonad sex steroids and gonadotropin-releasing hormone pulse frequency in the regulation of follicle-stimulating hormone secretion in men. J Clin Endocrinol Metab 2008;93:2686–92
   PubMedGoogle Scholar
• Yu IC, Lin HY, Sparks JD, et al. Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes 2014;63:3180–8
   PubMed Web of Science ®Google Scholar
• Cao J, Li J, Hao W, et al. Correlation of sex hormone and androgen receptor with diabetes mellitus in elderly men. Aging Male 2011;14:162–7
   PubMed Web of Science ®Google Scholar
• Delli Muti N, Tirabassi G, Lamonica GR, et al. Diabetes mellitus and late-onset hypogonadism: the role of Glu298Asp endothelial nitric oxide synthase polymorphism. Andrologia 2014. [Epub ahead of print] doi:10.1111/and.12339
   Google Scholar
• Schipf S, Haring R, Friedrich N, et al. Low total testosterone is associated with increased risk of incident type 2 diabetes mellitus in men: results from the Study of Health in Pomerania (SHIP). Aging Male 2011;14:168–75
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010;7:3495–03
   PubMed Web of Science ®Google Scholar
• Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828–37
   PubMed Web of Science ®Google Scholar
• Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with “diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol 2014. 2014:683515. doi:10.1155/2014/683515
   Google Scholar
• Haider A, Saad F, Doros G, Gooren L. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. Obes Res Clin Pract 2014;8:e339–49
   PubMed Web of Science ®Google Scholar
• Janjgava S, Zerekidze T, Uchava L, et al. Influence of testosterone replacement therapy on metabolic disorders in male patients with type 2 diabetes mellitus and androgen deficiency. Eur J Med Res 2014;19:56
   PubMedGoogle Scholar
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335–43
   PubMed Web of Science ®Google Scholar